"Efficacy in Adolescents of Continued Behavior Modification Following a Six Month Sibutramine-based Weight Management Intervention"

Exclusion Criteria

• •Weight loss ≥ 10 pounds in previous 3 months
• •Active gastrointestinal disorders (except GERD) such as peptic ulcer disease, irritable bowel disease, and gallbladder condition (in last 3 months); inflammable bowel disease (Crohn's ulcerative colitis, celiac sprue)
• •At least 2 out of 3 blood pressure readings either systolic or diastolic ≥ 95%ile for height and age or pulse ≥95 beats per minute at initial visit.
• •Drug treated diabetes mellitus or drug treated hypertension
• •Drugs and/or supplements administered for the first time or withdrawn during the past 6 months which have a significant impact on body weight or digestion (see Appendix D)
• •Inability or unwillingness to comply with protocol requirements, i.e. considered to be unfit for study participation, or unable to swallow pills.
• •Unwilling to avoid consumption of alcoholic beverages
• •Smoking or has started a smoking cessation program within the past six months
• •Previous treatment with prescription sibutramine (Meridia®)
• •History of recurrent nephrolithiasis
• •Major psychiatric or eating disorders (i.e., major depressive disorder, bipolar disorder, anorexia nervosa, bulimia or laxative abuse)
• •Kidney, liver, or thyroid disorder
• •Drugs that are contraindicated with concomitant use of sibutramine (Meridia®) within last 4 weeks (See Appendix E)
• •Cardiovascular disease (including arrhythmias, heart failure or congenital heart defect
• •History of bleeding problems, hemophilia
• •History of migraine headaches; seizures; a stroke or mini-stroke
• •History of Pulmonary hypertension
• •Osteopenia or osteoporosis
• •Self-report of current recreational drug use or overused prescription medications
• •History of glaucoma
• •Females who self-report pregnancy